This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Osteal Therapeutics, Inc. announced that it has received $50 million in funding from Zimmer Biomet Holdings, Inc., Johnson & Johnson Innovation - JJDC, Inc., HM Capital Management, LLC, GIDEON STRATEGIC PARTNERS LLC and other investors CI
Zimmer Biomet Holdings Insider Sold Shares Worth $1,474,582, According to a Recent SEC Filing MT
Zimmer Biomet's Limited Exposure to High-Growth Markets Spurs Revenue Concerns, UBS Says MT
Barclays Adjusts Price Target on Zimmer Biomet to $125 From $130 MT
Barclays Adjusts Price Target on Zimmer Biomet Holdings to $125 From $130 MT
Zimmer Biomet Outlines Growth Strategy Through 2027; Board Approves $2 Billion Stock Buyback MT
Zimmer Biomet Holdings, Inc. announces an Equity Buyback for $2,000 million worth of its shares. CI
Transcript : Zimmer Biomet Holdings, Inc. - Analyst/Investor Day
Zimmer Biomet Holdings, Inc. authorizes a Buyback Plan. CI
Osteal Therapeutics, Inc. announced that it expects to receive funding CI
Argus Upgrades Zimmer Biomet to Buy From Hold With $150 Price Target MT
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2024, Payable on or About July 31, 2024 CI
Raymond James Adjusts Price Target on Zimmer Biomet Holdings to $138 From $142 MT
UBS Adjusts Price Target on Zimmer Biomet Holdings to $112 From $109, Maintains Sell Rating MT
Truist Adjusts Zimmer Biomet Holdings' PT to $130 From $137, Keeps Hold Rating MT
Bernstein Adjusts Price Target on Zimmer Biomet to $133 From $132 MT
Jefferies Adjusts Price Target on Zimmer Biomet to $135 From $136 MT
Citigroup Adjusts Price Target on Zimmer Biomet to $134 From $140 MT
Morgan Stanley Adjusts Price Target on Zimmer Biomet to $130 From $135 MT
Jefferies Adjusts Zimmer Biomet Price Target to $135 From $136 MT
Citigroup Adjusts Zimmer Biomet Price Target to $134 From $140 MT
Morgan Stanley Adjusts Zimmer Biomet Price Target to $130 From $135 MT
Oppenheimer Adjusts Price Target on Zimmer Biomet Holdings to $155 From $150 MT
BTIG Adjusts Price Target on Zimmer Biomet to $139 From $138, Keeps Buy Rating MT
Transcript : Zimmer Biomet Holdings, Inc., Q1 2024 Earnings Call, May 02, 2024
Chart Zimmer Biomet Holdings, Inc.
More charts
Zimmer Biomet Holdings, Inc. specializes in designing, manufacturing, and selling orthopedic and dental reconstruction implants, spinal implants, and traumatology products. Net sales break down by family of products as follows: - reconstruction implants (57.5%): knees replacement (58.8% of net sales), hips replacement (41.2%); - surgical products and traumatology equipment (22.1%); - dental, spinal and craniomaxillofacial implants (12.8%); - other (7.6%): primarily orthopedic surgery materials and instruments used during post-operative rehabilitation. At the end of 2021, the group had approximately 30 production sites worldwide. Net sales are distributed geographically as follows: Americas (61.3%), Europe/Middle East/Africa (21.3%) and Asia/Pacific (17.4%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
112.6 USD
Average target price
136.4 USD
Spread / Average Target
+21.06%
Consensus
  1. Stock Market
  2. Equities
  3. ZBH Stock
  4. News Zimmer Biomet Holdings, Inc.
  5. Zimmer Biomet Partners with Three Pickleball Organizations in US